Form 4: Director Richard J. Rodgers Receives Opus Genetics Grant

Director Richard J. Rodgers was granted 24,367 restricted stock units in Opus Genetics, Inc. on April 20, 2026.

Summary

• Director Richard J. Rodgers acquired 24,367 restricted stock units (RSUs) of Opus Genetics, Inc. common stock.
• The transaction occurred on April 20, 2026, at a price of $0 per share.
• Following this transaction, the reporting person's total beneficial ownership increased to 343,022 shares.
• The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a company director.

Negatives

• None identified in this filing.

Risks

• Vesting is subject to the reporting person's continuing service through the vesting date.

Future Outlook

The RSUs are scheduled to vest on the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term performance and align leadership with shareholder interests in the biotechnology sector.

Comparison to Industry Standards

• The use of RSU grants for director compensation is consistent with standard practices for publicly traded biotech companies.
• The vesting schedule aligns with typical one-year cliff or annual meeting-based vesting cycles observed in the industry.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a standard equity compensation grant.

Next Steps

• Vesting of the 24,367 RSUs on the earlier of the one-year anniversary or the day prior to the next annual meeting.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, Director Compensation, Restricted Stock Units